TGA registration of biologic
Posted 2 years ago
Dupilumab (Dupixent® – Sanofi Genzyme) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy. Dupilumab is not currently listed on the Pharmaceutical Benefits Scheme. Treatment should be initiated and supervised by a dermatologist or immunologist.